PT4
PT4 is a therapeutic agent against Cutaneous leishmaniasis (CL) . PT4 is effective against both species of Leishmania, with IC50s of 125.18 and 233.18 μM for L. amazonensis and L. braziliensis, respectively. PT4 decreases of mitochondrial membrane potential and increases production of reactive oxygen species, which leads to parasite death. PT4 has a potent in vivo anti-inflammatory activity[1].
Product Specifications
CAS Number
1280738-47-7
UNSPSC
12352005
Target
Parasite; Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
Anti-infection; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/pt4.html
Solubility
10 mM in DMSO
Smiles
O=C1N(CCN2N=NC(C3=CC=CC=C3)=C2)C(C4=C1C=CC=C4)=O
Molecular Formula
C18H14N4O2
Molecular Weight
318.33
References & Citations
Leishmania amazonensisLeishmania braziliensis
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Leishmania
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
KRTAP25-1, CT (KRTAP25-1, KAP25.1, Keratin-associated protein 25-1) (MaxLight 405) discontinued
4933439F18Rik CRISPRa sgRNA lentivector (set of three targets)(Mouse)
Transcription Factor 4, T-cell Specific, HMG-box (TF4, TF7L2, Transcription Factor 7-like 2) discontinued